ERBB2 and breast cancer: Furthermore, we are not providing SLN-R results by tumor subtype, and it should be emphasized that higher TN/HER2 positive BC tumors’ chemosensitivity may have led to a selection bias, making it difficult to generalize the results as these populations are underrepresented.